These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6397946)

  • 1. Different mechanisms of TEM-1 and Oxa-1 mediated resistance to piperacillin in E. coli.
    Marre R; Borner K; Schulz E
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Dec; 258(2-3):287-95. PubMed ID: 6397946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of plasmid-encoded beta-lactamase resistance in Escherichia coli blood culture isolates.
    Huovinen S; Huovinen P; Torniainen K; Jacoby GA
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):651-5. PubMed ID: 3143575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problems in interpretation of piperacillin susceptibility of TEM-1 producing Escherichia coli in the disk diffusion test.
    Arstila T; Huovinen S; Huovinen P
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1066-7. PubMed ID: 1802698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
    London N; Thomson CJ; Amyes SG; Stobberingh E
    FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases.
    Marre R; Schulz E
    Arzneimittelforschung; 1988 Jul; 38(7):863-5. PubMed ID: 3061383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
    Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
    J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
    Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
    J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom.
    Karisik E; Ellington MJ; Pike R; Warren RE; Livermore DM; Woodford N
    J Antimicrob Chemother; 2006 Sep; 58(3):665-8. PubMed ID: 16870648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae.
    Shi WF; Zhou J; Qin JP
    Chin Med J (Engl); 2009 May; 122(9):1092-6. PubMed ID: 19493446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Cullmann W; Stieglitz M
    Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
    Rice LB; Carias LL; Bonomo RA; Shlaes DM
    J Infect Dis; 1996 Jan; 173(1):151-8. PubMed ID: 8537652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
    Kurpiel PM; Hanson ND
    J Antimicrob Chemother; 2012 Feb; 67(2):339-45. PubMed ID: 22117029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predominant β-lactamase genotypes of Escherichia coli isolates and induction and inhibition mechanisms of β-lactamase gene expression].
    Tan P; Wang Z; Sun A; Yan J; Zhao J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2015 May; 36(5):484-90. PubMed ID: 26080639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.